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Abstract: Excess production of melanin or its abnormal distribution, or both, can cause 
irregular hyperpigmentation of the skin, leading to melasma and age spots. To date, various 
quasi-drugs that prevent or improve hyperpigmentary disorders have been developed and 
officially approved by the Ministry of Health, Labor and Welfare of Japan. Many of these 
inhibit the activity of tyrosinase, an enzyme required for melanin synthesis, for example, 
by  competitive  or  non-competitive  inhibition  of  its  catalytic  activity,  by  inhibiting  its 
maturation, or by accelerating its degradation. In this review, we categorize the quasi-drugs 
developed in Japan to prevent or treat hyperpigmentary disorders, or both, and discuss 
perspectives for future development. 
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1. Introduction 
Skin  lightening  or  whitening  quasi-drugs  (QDs),  a  category  created  in  Japan  for  functional 
cosmetics, contain active ingredients that prevent or improve hyperpigmentation in disorders, such as 
melasma and solar lentigo. To be sold in Japan, they must be approved by the Japanese Ministry of 
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Health,  Labor  and  Welfare  (MHLW).  Although  much  still  remains  unknown  about  the  causes  of 
hyperpigmentation,  it  is  thought  that  the  localized  and  irregular  over-production  of  melanin  by 
melanocytes in the basal layer of the epidermis or the retention of melanin in the epidermis due to 
aberrant epidermal turnover, or both, play a role in hyperpigmentary disorders. Development of topical 
materials to treat these cosmetic hyperpigmentary disorders, with the goal of reducing excess melanin 
production  and  promoting  clearing  of  accumulated  melanin  from  the  epidermis,  has  contributed 
significantly to the understanding of melanogenesis and pigmentation as physiological processes. 
2. Instances of Skin Lightening QDs Developed in Japan 
Until the late 1980s, ascorbic acid (also termed Vitamin C) and placental extracts were used as skin 
lightening QDs in Japan. Since 1988, starting with the approval of kojic acid by the MHLW, many 
companies have begun to develop proprietary QDs. 
2.1. Ascorbic Acid and Its Derivatives 
Melanin synthesis is regulated by the rate-limiting enzyme, tyrosinase, a membrane-bound copper-
containing  glycoprotein,  which  initiates  the  biosynthetic  pathway  of  melanin  by  catalyzing  the 
hydroxylation of tyrosine to DOPA. Since subsequent reactions in the melanin synthetic pathway, e.g., 
the conversion of DOPA to DOPAquinone, as well as other non-enzymatic reactions, are oxidative 
reactions, antioxidants such as ascorbic acid, are effective inhibitors of melanin synthesis. Ascorbic 
acid and its derivatives are the most popular skin lightening QDs that have ever been used in Japan. 
Examples of ascorbic acid derivatives are magnesium L-ascorbic acid 2-phosphate (QD approval 
was  obtained  by  the  Takeda  Pharmaceutical  Company  Limited  in  1988),  sodium  L-ascorbic  acid  
2-phosphate, L-ascorbic acid 2-glucoside (obtained by Shiseido Co., Ltd. and Kaminomoto Co., Ltd. 
in  1994),  and  L-ascorbic  acid ethyl  ester (obtained  by Shiseido  Co., Ltd.  in  2005).  Although  the 
inhibitory mechanism of skin lightening by L-ascorbic acid ethyl ester is to prevent polymerization of 
melanin monomers involved in the immediate pigment darkening of the skin induced by ultraviolet 
light A (UVA) (320-400 nm) [1,2], the inhibitory mechanisms of melanin synthesis by ascorbic acid 
and its other derivatives are mainly antioxidative in nature. L-Ascorbic acid 2-glucoside has been 
shown to maintain prolonged biological activity of ascorbic acid longer than sodium L-ascorbic acid  
2-phosphate, a conventional ascorbic acid [3]. In clinical trials, a 10% magnesium L-ascorbic acid  
2-phosphate-containing formulation was shown to be effective for reducing melasma and age spots [4]. 
A 2% L-ascorbic acid 2-glucoside-containing cream was shown to accelerate the disappearance of 
ultraviolet light B (UVB) (280-320 nm)―induced hyperpigmentation of the skin [5]. 
2.2. Placental Extracts 
Placental extracts have long been used as an active ingredient for skin lightening QDs, together 
with ascorbic acid and its derivatives. Previously, a bovine-derived placental extract was the primary 
commercial source. However, swine-derived placental extracts are now used because of concern over 
mad cow disease. Various amino acids and minerals are at high concentrations in placental extracts, 
and the efficient inhibition of melanin synthesis and the enhancement of melanin removal from the Int. J. Mol. Sci. 2010, 11                       
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skin, due to increased epidermal turnover have been reported [6,7]. Interestingly, although placental 
extract has a strong history of use to decrease hyperpigmentation, it has also been shown to increase 
melanogenesis.  The  lipid  fraction  of  human  placental  extract  was  reported  to  increase  melanin 
synthesis via the enhancement of tyrosinase gene expression [8]. 
2.3. Kojic Acid (Obtained by Sansho Seiyaku Co., Ltd. in 1988) 
Kojic acid, a pyrone derivative obtained from the fermentation process of Japanese liquor, is known 
to have an antibacterial activity. Kojic acid was shown to inhibit the activity of tyrosinase by chelating 
copper atoms in its active site [9]. In clinical trials, a 1% kojic acid-containing formulation was shown 
to  be  effective  for  treating  hyperpigmentary  disorders,  such  as  melasma,  post-inflammatory 
hyperpigmentation, age spots, and freckles [10]. 
The MHLW in March, 2003 notified suppliers of kojic acid to delay manufacture or import because of 
caution about possible carcinogenic effects [11]. However, after revaluation in November, 2005, kojic 
acid is now accepted to be safe as a cosmetic ingredient, and continues to be used as a skin lightening  
QD [12]. 
2.4. Arbutin (Obtained by Shiseido Co., Ltd. in 1989) 
Arbutin,  a  naturally  occurring  β-D-glucopyranoside  derivative  of  hydroquinone,  is  found  in 
cowberry leaves, and inhibits tyrosinase activity competitively, but at non-cytotoxic concentrations in 
cultured melanocytes [13]. A 3% arbutin-containing formulation was shown to be effective for treating 
hyperpigmentary disorders, such as melasma [14]. 
2.5. Ellagic Acid (Obtained by the Lion Corporation in 1996) 
Ellagic acid is a naturally occurring polyphenol found in a variety of plants, such as strawberries, 
geraniums, and green tea. The inhibitory effect of ellagic acid on melanin synthesis is similar to kojic 
acid, i.e., ellagic acid inhibits tyrosinase activity by chelating copper atoms in its active site [15]. A 
0.5%  ellagic  acid-containing  cream  was  shown  to  be  effective  for  treating  UVB-induced 
hyperpigmentation of the skin [16]. 
2.6. Chamomilla Extract (Obtained by the Kao Corporation in 1998) 
Chamomilla extract has been used as a traditional anti-inflammatory agent, and is the only one so 
far, in Japan, that has been approved as a skin lightening QD from botanical extracts. It has been 
shown  that  keratinocytes  secrete  endothelin-1,  a  type  of  inflammatory  cytokine,  which  activates 
melanocytes when UV is irradiated on the epidermis [17]. Chamomilla extracts have been shown to 
act as an antagonist for endothelin-receptor binding, which mediates cell-to-cell signaling between 
keratinocytes  and  melanocytes.  This  antagonism  leads  to  the  inhibition  of  melanin  synthesis  in 
melanocytes [18]. Until then, all earlier skin lightening QDs had been developed to inhibit tyrosinase 
activity. In contrast, the chamomilla extract is a unique QD focused on affecting the keratinocytes that 
surround melanocytes. A 0.5% chamomilla extract-containing cream was shown to be effective for 
treating UVB-induced hyperpigmentation of the skin [19,20]. Int. J. Mol. Sci. 2010, 11                       
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2.7. 4-n-Butylresorcinol (Rucinol
®) (Obtained by POLA in 1998) 
Rucinol
®  was  selected  by  screening  synthetic  resorcinol  derivatives  that  can  elicit  strong 
competitive inhibition of tyrosinase activity. Melanin synthesis is catalyzed by tyrosinase, together 
with tyrosinase-related proteins (TRP) –1 and –2, and Rucinol
® has been shown to inhibit melanin 
synthesis in cultured mouse melanocytes via direct inhibition not only of tyrosinase activity [21], but 
also of TRP-1 activity [22]. A 0.3% Rucinol
®-containing lotion was shown to be effective for treating 
hyperpigmentary disorders, such as melasma [22]. 
2.8. Linoleic Acid (Obtained by Sunstar Inc. in 2001) 
Linoleic acid is an unsaturated fatty acid (C18:2) derived from hydrolyzed botanical oils, such as 
safflower,  and  is  a  major  component  of  biological  cell  membranes.  Tyrosinase  is  degraded 
endogenously  in  melanocytes  [23],  and  linoleic  acid  has  been  shown  to  accelerate  tyrosinase 
degradation, and to decrease tyrosinase levels. These actions lead to the down-regulation of melanin 
synthesis  [24].  In  clinical  trials,  topical  application  of  a  0.1%  linoleic  acid-containing  liposomal 
formulation has been shown to be effective for treating melasma [25] and to lighten UVB-induced 
hyperpigmentation of the skin [26,27]. 
2.9. Tranexamic Acid (Obtained by Shiseido Co., Ltd. in 2002) 
Tranexamic  acid  has  been  used  as  a  traditional  hemostatic  medicine,  and  is  known  as  an  oral 
medicine for treating melasma [28]. Plasmin, a kind of protease in the  blood serum, functions to 
enhance the intracellular release of arachidonic acid, a precursor of prostanoid [29], and also to elevate 
alpha-melanocyte stimulating hormone processed from pro-opiomelanocortin [30]. Both arachidonic 
acid  and  alpha-melanocyte  stimulating  hormone  can  activate  melanin  synthesis  by  melanocytes. 
Therefore,  the  anti-plasmin  activity  of  tranexamic  acid  is  thought  to  play  a  role  in  its  topical 
effectiveness for treating melasma. 
2.10. 4-Methoxy Potassium Salicylate (4MSK) (Obtained by Shiseido Co., Ltd. in 2003) 
The  inhibitory  mechanism  of  4MSK  on  melanin  synthesis  was  shown  to  be  the  competitive 
inhibition of tyrosinase activity. This mechanism is similar to those of arbutin and Rucinol
®. 
2.11. Adenosine Monophosphate Disodium Salt (Obtained by Otsuka Pharmaceutical Co., Ltd. in 
2004) 
Adenosine monophosphate has the potency to increase the amount of intracellular glucose uptake, 
which is necessary for the biosynthesis of adenosine triphosphate, a source of intracellular energy. 
Therefore, adenosine monophosphate disodium salt accelerates epidermal turnover due to the elevated 
intracellular energy metabolism, which leads to the excretion of melanin from the skin, i.e., adenosine 
monophosphate  prevents  the  accumulation  of  melanin  in  the  skin  [31].  A  3%  adenosine 
monophosphate  disodium  salt-containing  formulation  was  shown  to  be  effective  for  treating 
hyperpigmentary disorders, such as melasma [31]. Int. J. Mol. Sci. 2010, 11                       
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2.12. 5,5’-Dipropyl-biphenyl-2,2’-diol (Magnolignan
®) (Obtained by Kanebo Cosmetics Inc. in 2005) 
Magnolignan
® is a biphenyl compound and a kind of polyphenol that has a structure similar to the 
magnolol and honokiol of Magnolia obovata. Tyrosinase is known to mature due to its glycosylation in 
the  endoplasmic  reticulum  (ER)  and  Golgi  apparatus;    Magnolignan
®  inhibits  the  maturation  of 
tyrosinase,  which  leads  to  decreased  melanin  synthesis  [32].  A  0.5%  Magnolignan
®-containing 
formulation was shown to be effective for treating UVB-induced hyperpigmentation of the skin [33] 
and is also effective in treating hyperpigmentary disorders, such as melasma and senile lentigo [34]. 
2.13. 4-(4-Hydroxyphenyl)-2-butanol (4-HPB) (Obtained by Kanebo Cosmetics Inc. in 2007) 
4-HPB is a phenol compound found in extracts of White Birch and Nikko Maple. The inhibitory 
mechanism  of  4-HPB  on  melanin  synthesis  was shown to  be  due  to  its  competitive inhibition  of 
tyrosinase activity. 
2.14. Tranexamic Acid Cetyl Ester Hydrochloride (Obtained by CHANEL .KK in 2009) 
The effect of tranexamic acid cetyl ester hydrochloride in treating hyperpigmentary disorders is due 
to the inhibition of UVB-induced inflammation, which leads to the quiescence of active melanocytes. 
This mechanism is similar to those of chamomilla extract and tranexamic acid. 
3. Classification of the Mechanisms of QDs 
To date, many private company-originated QDs have been developed that are based on various 
mechanisms of skin lightening or whitening efficacy (Table 1). The major target of those QDs is 
tyrosinase  in  melanocytes,  while  some  QDs  work  on  keratinocytes  or  on  epidermal  metabolism. 
Among the melanocyte-targeted QDs, the inhibitory mechanism targeting tyrosinase activity can be 
divided into two groups, i.e., the inhibition of tyrosinase catalytic activity, such as anti-oxidation, the 
chelation of copper atoms in tyrosinase active site, and competitive inhibition, while the other category 
is the decrease of tyrosinase protein levels, which also leads to the inhibition of tyrosinase activity, 
such  as  accelerating  tyrosinase  degradation  or  inhibiting  tyrosinase  maturation,  which  eventually 
forwards immature tyrosinase to the ER-associated protein degradation pathway [35]. An efficient way 
to decrease tyrosinase protein levels is to reduce tyrosinase mRNA levels, as already reported for 
lipoic acid [36] and sphingosine-1-phosphate [37]. However, compounds that regulate transcription 
have not yet been approved by the MHLW of Japan for skin lightening QDs. 
On the other hand, the keratinocyte-targeted QDs inhibit the activation of melanocytes by blocking 
or reducing UVB-induced inflammatory cytokines, and melanocyte quiescence eventually leads to 
decreased tyrosinase activity. In addition, the epidermis-targeted QDs elicit excretion of melanin from 
the  epidermis,  which  leads  to  recovery  from  hyperpigmentary  disorders.  This  is  a  special  skin 
lightening strategy that is substantially independent from melanocyte function. 
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Table 1. Mechanistic classification of skin lightening QDs approved by the MHLW of Japan. 
Target  Mechanism  Detail  Skin Lightening QD 
Melanocyte 
Inhibition of 
tyrosinase activity 
Anti-oxidation  Ascorbic acid/derivatives 
Chelating copper 
atoms 
Kojic acid     Ellagic acid 
Competitive 
inhibition 
Arbutin          Rucinol®   
4MSK              4-HPB 
 
Decrease of 
tyrosinase 
protein level 
Acceleration of Tyr 
degradation 
Linoleic acid 
Inhibition of Tyr 
maturation 
Magnolignan® 
Keratinocyte 
Inhibition of KC-
MC signaling￿  
Inhibition of UV 
inflammation 
Chamomilla extract 
Tranexamic acid/derivative￿  
Epidermis 
Acceleration 
of epidermal 
turnover 
Desquamation 
of melanin 
Placental extract 
Adenosine mono-
phosphate 
KC: keratinocyte, MC: melanocyte, Tyr: tyrosinase, UV: ultraviolet light 
 
4. Perspectives 
Nowadays, many of the hyperpigmentary disorders of the skin can be remedied by various laser 
therapies. Moreover, the chemical peeling of the stratum corneum using  α-hydroxy acids, such as 
glycolic acid [38] and lactic acid [39], has also been shown to be modestly effective for treating 
hyperpigmentary disorders, such as melasma, due to the desquamation of melanin from the epidermis. 
In addition, this accelerated desquamation is often used to enhance the efficacy of other treatments. 
Hydroquinone is currently the gold standard topical drug for dyschromia. It remains somewhat 
controversial  however,  and  at  one  time,  was  available  only  by  prescription,  because  it  has  been 
associated with several adverse events. For example, vitiligo-like effects and exogenous ochronosis 
have been reported after hydroquinone use [40]. In addition, the US FDA has stated that hydroquinone 
cannot be ruled out as a potential carcinogen and therefore is prohibited for use in cosmetics. However, 
a  change  of  Japanese  Pharmaceutical  Law  in  2001  now  allows  the  use  of  hydroquinone  as  an 
ingredient of cosmetic formulations at lower and presumably safer concentrations. Hyperpigmentary 
conditions indicated for skin lightening QDs developed in Japan are limited, that is, clinical trials have 
demonstrated their efficacy mostly against melasma and solar lentigo. Nevertheless, those QDs remain 
popular,  especially  in  Asian  cosmetic  markets,  as  a  convenient  means  to  treat  non-pathological 
hyperpigmentary disorders of the skin. 
To  date,  various  skin  lightening  QDs  have  been  developed  based  on  a  variety  of  functional 
mechanisms. When it comes to the investigation of skin lightening or whitening agents at a global 
scale, a large number of melanogenesis inhibitors, such as inhibitors of tyrosinase mRNA transcription, 
tyrosinase glycosylation, and tyrosinase catalytic activity, and accelerators of tyrosinase degradation 
have been reported [35,41-45]. Those findings will be further expanded and utilized for developing 
different strategies from previous theories for QDs, for instance, the inhibition of melanosome transfer Int. J. Mol. Sci. 2010, 11                       
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from melanocytes to keratinocytes. Examples of inhibitors of melanosome transfer include soybean 
trypsin inhibitor [46], niacinamide [47], and centaureidin [48]. Since various types of hyperpigmentary 
disorders  are  based  on  different  mechanisms,  multi-functional  topical  formulations  that  combine 
existing skin lightening QDs, including not only inhibition of melanin synthesis, but also inhibition of 
inflammation or acceleration of epidermal turnover, or both, may be better strategies for increasing the 
efficacy of products to treat hyperpigmentary disorders, such as melasma and solar lentigo. 
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